Literature DB >> 1560825

Molecular cloning and expression of a rat V1a arginine vasopressin receptor.

A Morel1, A M O'Carroll, M J Brownstein, S J Lolait.   

Abstract

The neurohypophyseal hormone arginine vasopressin has diverse actions, including the inhibition of diuresis, contraction of smooth muscle, stimulation of liver glycogenolysis and modulation of adrenocorticotropic hormone release from the pituitary. Arginine vasopressin receptors are G protein-coupled and have been divided into at least three types; the V1a (vascular/hepatic) and V1b (anterior pituitary) receptors which act through phosphatidylinositol hydrolysis to mobilize intracellular Ca2+, and the V2 (kidney) receptor which is coupled to adenylate cyclase. We report here the cloning of a complementary DNA encoding the hepatic V1a arginine vasopressin receptor. The liver cDNA encodes a protein with seven putative transmembrane domains, which binds arginine vasopressin and related compounds with affinities similar to the native rat V1a receptor. The messenger RNA corresponding to the cDNA is distributed in rat tissues known to contain V1a receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560825     DOI: 10.1038/356523a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  77 in total

Review 1.  The thymic education of developing T cells in self neuroendocrine principles.

Authors:  V Geenen; F Robert; H Martens; D De Groote; P Franchimont
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

2.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor.

Authors:  H Hausmann; A Richters; H J Kreienkamp; W Meyerhof; H Mattes; K Lederis; H Zwiers; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 3.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

4.  Hormonal regulation of nuclear permeability.

Authors:  Elizabeth M O'Brien; Dawidson A Gomes; Sona Sehgal; Michael H Nathanson
Journal:  J Biol Chem       Date:  2006-12-07       Impact factor: 5.157

5.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

6.  Receptor-oriented intercellular calcium waves evoked by vasopressin in rat hepatocytes.

Authors:  T Tordjmann; B Berthon; E Jacquemin; C Clair; N Stelly; G Guillon; M Claret; L Combettes
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 7.  Role of various neurotransmitters in mediating the long-term endocrine consequences of prenatal alcohol exposure.

Authors:  Soon Lee; Irene Choi; Sang Kang; Catherine Rivier
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

9.  Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling.

Authors:  Elena A Zalyapin; Richard Bouley; Udo Hasler; Jean-Pierre Vilardaga; Herbert Y Lin; Dennis Brown; Dennis A Ausiello
Journal:  Kidney Int       Date:  2008-08-27       Impact factor: 10.612

10.  Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei.

Authors:  Jia-Da Li; Katherine J Burton; Chengkang Zhang; Shuang-Bao Hu; Qun-Yong Zhou
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-03       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.